ERBB2 and breast cancer: Recently, researchers showed that good prognosis could be detected via abnormal expression of TMEM16A in BC patients who are PR-positive or HER2-negative after tamoxifen treatment, especially in those patients along with the silence of Ki67 (Wu et al., 2017; Wu et al., 2015).